Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

2014 ◽  
Vol 50 (3) ◽  
pp. 563-569 ◽  
Author(s):  
Jonas Busch ◽  
Christoph Seidel ◽  
Irena Goranova ◽  
Barbara Erber ◽  
Robert Peters ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Overall Survival ◽  
Targeted Therapy ◽  
Growth Factor ◽  
Renal Cell ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
First Line ◽  
Endothelial Growth Factor

scholarly journals Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors

2016 ◽  
Vol 10 (11-12) ◽  
pp. 242 ◽  
Author(s):  
Naveen S. Basappa
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Targeted Therapy ◽  
Growth Factor ◽  
Renal Cell ◽  
Vascular Endothelial ◽  
Second Line ◽  
First Line ◽  
Line Setting ◽  
Endothelial Growth Factor

Targeted therapy for metastatic renal cell carcinoma (mRCC) was introduced a decade ago, and since then a number of therapeutic options have been developed. Vascular endothelial growth factor targeted therapy is the widely accepted first-line option for mRCC. After progression, treatment in the second-line setting has typically been with either axitinib or everolimus. However, with the advent of several new agents demonstrating efficacy in the second-line setting, including nivolumab, cabozantinib, and the combination of lenvatinib and everolimus, the treatment paradigm has shifted toward these novel therapies with improved patient outcomes.

Sign in / Sign up

Export Citation Format

Share Document